Cardamyst

(Etripamil)

Phase 3Small molecule

Cardamyst is one of 28 small molecule programs targeting Paroxysmal supraventricular tachycardia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Paroxysmal Supraventricular TachycardiaActive, not recruiting

Atrial FibrillationActive, not recruiting

Paroxysmal Supraventricular TachycardiaPhase 3

Active, not recruiting

Atrial FibrillationPhase 3

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Cardamyst

MMilestone Pharmaceuticals Inc.

Phase 3

2 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Imbruvica

1 5

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Brukinsa

BBeOne Medicines

Preclinical

1 7

Anticoagulants

Sanofi

Preclinical

2 8

Direct Anticoagulant

Bayer

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Warfarin Sodium

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Pediatric Patients

NCT05763953

Q1 2030

Phase 3Not yet recruiting

Atrial Fibrillation

NCT06716021

Clinical

Trials by Indication[1]

Paroxysmal supraventricular tachycardia5 trials

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

Terminated·MMilestone Pharmaceuticals Inc.·Phase 3·NCT03464019·1,097 enrolled

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

Completed·MMilestone Pharmaceuticals Inc.·Phase 3·NCT04072835·1,116 enrolled

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Terminated·MMilestone Pharmaceuticals Inc.·Phase 3·NCT03635996·169 enrolled

Show 2 more trials

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

Completed·CCorxel Pharmaceuticals·Phase 3·NCT05410860·500 enrolled

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Enrolling by invitation·MMilestone Pharmaceuticals Inc.·Phase 3·NCT04952610·130 enrolled

Atrial Fibrillation2 trials

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

Not yet recruiting·MMilestone Pharmaceuticals Inc.·Phase 3·NCT06716021·750 enrolled

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Completed·MMilestone Pharmaceuticals Inc.·Phase 2·NCT04467905·69 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Completed·MMilestone Pharmaceuticals Inc.·Phase 2·NCT02296190·199 enrolled

Pediatric Patients1 trial

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

Recruiting·MMilestone Pharmaceuticals Inc.·Phase 2·NCT05763953·60 enrolled

Unspecified1 trial

A Study of Etripamil in Healthy Subjects

Completed·CCorxel Pharmaceuticals·Phase 1·NCT05511870·12 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 12, 2025

CARDAMYST

NDA NDA218571

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Etripamil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Etripamil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Etripamil. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA218571). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Cardamyst. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Milestone Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMilestone Pharmaceuticals Inc.

Patent Landscape[5]

Patent Cliff

Jun 19, 2028

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10010522Jun 19, 2028

9463179Jun 19, 2028

10010523Jun 19, 2028

9227918Jun 19, 2028

10117848Apr 13, 2036

1 more patents

12257224Jul 15, 2042

Cardamyst

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2030

Trials by Indication[1]

Paroxysmal supraventricular tachycardia5 trials

Atrial Fibrillation2 trials

Efficacy and Safety1 trial

Pediatric Patients1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News